Biotech Analyst Rama, along with Dr. Haas-Kogan, Chairperson of the Dept of Radiation Oncology at the Dana-Farber Cancer Institute, discuss considerations for Day One Biopharmaceuticals (DAWN) Ojemda launch for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) on an Analyst/Industry conference call to be held on April 29 at 11 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One comments from call weighing on sentiment, says BofA
- Xoma earns $9M milestone as FDA grants approval of Day One’s NDA for OJEMDA
- Day One Biopharmaceuticals Achieves FDA Approval and Rare Voucher
- Day One Biopharmaceuticals price target raised to $33 from $30 at Needham
- Day One should rally to $17.50-$18 on approval, says JonesResearch
